Business

  • Business |

    As more blockbuster drugs come off patent, generic drugmakers face a changing landscape. Meredith Wadman looks at their strategies for survival.

    • Meredith Wadman
  • Business |

    Although cargo vessels are currently spared emissions restrictions, the industry is planning ahead. Kurt Kleiner looks at the ideas being floated to improve energy efficiency on the high seas.

    • Kurt Kleiner
  • Business |

    The flat-screen television boom has materials scientists scrambling to replace the valuable metal oxide that coats the screens. Andrea Chipman reports.

  • Business |

    Sustained high oil prices won't be enough to make coal liquefaction economically viable without large-scale public investment. Katharine Sanderson reports.

  • Business |

    Life for scientific entrepreneurs in Russia can be fraught with difficulty. Alison Abbott meets one who has ridden the rapids for more than a decade.

  • Business |

    Europe's largest technology company is switching its priorities, even as it faces a growing bribery scandal. Quirin Schiermeier reports.

  • Business |

    Can an expanded loan guarantee programme dispel US power companies' hesitation about resuming construction of nuclear power plants? Geoff Brumfiel investigates.

  • Business |

    Plans to revamp drug regulation in China have yet to convince the sceptics, as Jane Qiu reports.

  • Business |

    Smart investors who know the drugs business well are helping to make Zurich's stock market a popular place for biotechnology firms to raise money. Andrea Chipman reports.

  • Business |

    The safety problems that brought down Vioxx have tainted a whole class of drugs. Meredith Wadman examines their chances of a comeback.

  • Business |

    The US Patent and Trade Office has cracked open the door on its normally closed patent evaluation process. Heidi Ledford looks at how its peer-review project is faring.

  • Business |

    As a fast-growing emitter of greenhouse gases, the aviation industry is under intense pressure to improve its fuel efficiency. Kurt Kleiner surveys its options.

  • Business |

    Most drug companies have tried to avoid making enemies of AIDS activist groups. But Abbott Laboratories' patience has snapped, as Erika Check reports.

  • Business |

    As a BP project to capture carbon dioxide from a power station bites the dust, supporters argue that a major opportunity for Britain has been lost. Andrea Chipman reports.

  • Business |

    A rash of problems has knocked some of the shine off one of the world's top biotechnology companies, as Meredith Wadman reports.

  • Business |

    Light-emitting diodes are seen by many as the light source of the future. But as Kurt Kleiner reports, their adaptation will take time.

  • Business |

    Support for copycat versions of biotechnology drugs is growing quickly in the US Congress. Meredith Wadman reports.

  • Business |

    A handful of pioneers are trying to bring algae-based biofuels back from a near-death experience. Amanda Leigh Haag reports.

  • Business |

    Despite its critics, the Alternative Investment Market could still be attractive to America's small, innovative companies, reports Andrea Chipman.

  • Business |

    Long dismissed as too expensive or impractical, mining the sea floor for metals is gaining a new foothold. Mark Schrope reports on two companies hoping to take the plunge.

  • Business |

    As AstraZeneca shells out $15 billion for a mid-sized US biotech firm, Heidi Ledford reports on the startling cost of staying in the drugs business.

  • Business |

    A patent ruling has delivered a serious blow to one US state's hopes of a biotechnology boom. Erika Check reports.

  • Business |

    A licensing dispute over fuel additives could spell trouble for one of Britain's nanotechnology stars, as Katharine Sanderson reports.

  • Business |

    Fresh laws on the regulation of medicines are working their way through the US Congress — but will they strike the right balance between public safety and innovation? Meredith Wadman investigates.

  • Business |

    Car companies know that plastic parts made from plants will appeal to 'green' customers. But as Ichiko Fuyuno reports, their progress has been painfully slow.